In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bacterial infection Dx firm raises €18.5m

This article was originally published in Clinica

Executive Summary

A consortium of European venture capital firms have invested €18.5m ($27.1m) of series A financing in German molecular diagnostics start-up Curetis. The Holzgerlingen-based company will use the proceeds to complete development of its first range of products and gain the necessary regulatory approvals to commercialise them. The initial products will focus on diagnosing severe bacterial infections, such as pneumonia. Investors in Curetis include Life Sciences Partners; BioMedPartners; ERP-Startfonds of the KfW Bankengruppe; and aeris CAPITAL, which also provided the company with seed funding.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts